1013-00001 · Genome Dx Therapeutics Inc · Transaction Documents

ip-security-agreement-execution.docx DOCUMENT Finance & Banking

9 / 12 ← → ✕

INTELLECTUAL PROPERTY SECURITY AGREEMENT

(Short-Form Patent and Trademark Security Agreement for Recording with the United States Patent and Trademark Office)

March 6, 2026

This INTELLECTUAL PROPERTY SECURITY AGREEMENT (this "Agreement") is entered into as of March 6, 2026, by and between:

GENOME DX THERAPEUTICS INC., a Delaware corporation (the "Grantor" or "GenomeDx"), with its principal place of business at 450 Genome Way, Suite 300, South San Francisco, California 94080;

and

PACIFIC FIDUCIARY SERVICES INC., a California corporation (the "Collateral Agent"), with its principal office at 350 Mission Street, Suite 1200, San Francisco, California 94105, acting in its capacity as Collateral Agent for the benefit of the Secured Parties (as defined in the Security Agreement referenced below).

The Grantor and the Collateral Agent are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

RECITALS

WHEREAS:

A. GenomeDx, Pinnacle Venture Lending Corp., a Delaware corporation, in its capacity as Administrative Agent and a Lender, Cobalt Life Sciences Fund III, L.P., a Delaware limited partnership, in its capacity as a Lender, and Pacific Fiduciary Services Inc., in its capacity as Collateral Agent, have entered into that certain Bridge Loan Agreement, dated as of March 6, 2026 (as may be amended, restated, supplemented, or otherwise modified from time to time, the "Bridge Loan Agreement"), providing for a senior secured bridge loan facility in the aggregate principal amount of Fifteen Million Dollars ($15,000,000);

B. GenomeDx, as Grantor, and Pacific Fiduciary Services Inc., as Collateral Agent, have entered into that certain Security Agreement, dated as of March 6, 2026 (as may be amended, restated, supplemented, or otherwise modified from time to time, the "Security Agreement"), pursuant to which the Grantor granted to the Collateral Agent, for the benefit of the Secured Parties, a first-priority security interest in substantially all of the Grantor's assets, including, without limitation, its intellectual property;

C. This intellectual Property Security Agreement is being executed and delivered to supplement the Security Agreement and for the specific purpose of recording the Collateral Agent's security interest in the Grantor's patents, patent applications, trademarks, and trademark applications with the United States Patent and Trademark Office (the "USPTO"), in order to provide notice-filing perfection with respect to registered intellectual property collateral and to satisfy the requirements of 35 U.S.C. § 261 and 15 U.S.C. § 1060 with respect to security interests in patents and trademarks, respectively;

D. GenomeDx is the sole and exclusive owner of the patents, patent applications, trademarks, and trademark applications listed on the Schedules attached hereto and incorporated herein by reference; and

E. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Security Agreement or, if not defined therein, in the Bridge Loan Agreement.

NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

SECTION 1. GRANT OF SECURITY INTEREST

The Grantor hereby grants, assigns, and pledges to the Collateral Agent, for the ratable benefit of the Secured Parties, a continuing first-priority security interest in and to all of the Grantor's right, title, and interest in, to, and under the following property, whether now owned or hereafter acquired (collectively, the "IP Collateral"):

(a) All patents and patent applications of the United States listed on Schedule A attached hereto and incorporated herein by reference, together with all reissues, continuations, continuations-in-part, divisionals, extensions, renewals, and re-examinations thereof, and all rights therein provided by international treaties or conventions (collectively, the "Patent Collateral");

(b) All trademarks, service marks, trade names, trade dress, trademark applications, and trademark registrations of the United States, if any, listed on Schedule B attached hereto and incorporated herein by reference, together with all renewals, extensions, and applications therefor and the goodwill of the business connected with the use of and symbolized by such trademarks (collectively, the "Trademark Collateral");

(c) All rights to sue or otherwise recover for past, present, and future infringement, misappropriation, dilution, or other violation of any of the foregoing, including the right to collect damages, profits, and any other monetary relief;

(d) All licenses, sublicenses, royalties, income, payments, and other rights and benefits arising from or relating to any of the foregoing, whether now existing or hereafter arising; and

(e) All proceeds and products of any and all of the foregoing, in whatever form, including cash, negotiable instruments, and other forms of payment or exchange.

The grant of the security interest set forth in this Section 1 supplements, and does not in any way limit, restrict, or modify, the security interest granted under the Security Agreement. The IP Collateral constitutes a subset of the "Collateral" (as defined in the Security Agreement), and the security interest granted herein is subject to the same exceptions, limitations, and carve-outs set forth in the Security Agreement, including, without limitation, the exclusion of assets subject to the first-priority lien of Ridgeline Capital Partners LLC under GenomeDx's existing equipment financing facility, as more particularly described in the Bridge Loan Agreement, and the intercreditor arrangements set forth in that certain Intercreditor Agreement, dated as of March 6, 2026, by and among the Collateral Agent, Ridgeline Capital Partners LLC, and the Grantor (the "Intercreditor Agreement").

SECTION 2. SECURED OBLIGATIONS

The security interest granted herein secures the prompt and complete payment and performance of all Secured Obligations (as defined in the Security Agreement), including, without limitation, all obligations of the Grantor arising under or in connection with (a) the Bridge Loan Agreement, including all principal, interest, fees, premiums, indemnities, and expenses payable thereunder, (b) the Security Agreement, (c) the Warrant Agreements (as defined in the Bridge Loan Agreement), and (d) all other Loan Documents (as defined in the Bridge Loan Agreement), in each case whether now existing or hereafter arising, direct or indirect, absolute or contingent, and howsoever evidenced.

SECTION 3. RELATIONSHIP TO SECURITY AGREEMENT

This Agreement supplements the Security Agreement and shall be construed in conjunction with and as an integral part of the Security Agreement. Nothing contained herein shall be deemed to amend, modify, limit, or otherwise affect the scope or terms of the security interest granted under the Security Agreement, which security interest remains in full force and effect in accordance with its terms.

In the event of any conflict or inconsistency between the terms of this Agreement and the terms of the Security Agreement, the terms of the Security Agreement shall govern and control in all respects.

The rights and remedies of the Collateral Agent hereunder are in addition to, and not in limitation of, the rights and remedies available to the Collateral Agent and the Secured Parties under the Security Agreement, the Bridge Loan Agreement, and applicable law, including the California Uniform Commercial Code and the federal patent and trademark statutes of the United States.

SECTION 4. REPRESENTATIONS AND WARRANTIES OF THE GRANTOR

The Grantor hereby represents and warrants to the Collateral Agent and the Secured Parties as follows, each of which representations and warranties shall survive the execution and delivery of this Agreement:

4.1 Ownership. The Grantor is the sole and exclusive owner of the entire right, title, and interest in and to each item of IP Collateral listed on Schedules A and B hereto, free and clear of all liens, claims, encumbrances, charges, and security interests other than Permitted Liens (as defined in the Bridge Loan Agreement) and the security interest created hereby. No other person or entity has any ownership interest, legal or equitable, in any of the IP Collateral, except as may be expressly reflected on the face of the applicable Schedule.

4.2 Validity. To the Grantor's knowledge, after reasonable inquiry, each issued patent listed on Schedule A hereto is valid and enforceable, and no claim of invalidity or unenforceability has been asserted against any such patent by any third party. Each pending patent application listed on Schedule A hereto is being duly and diligently prosecuted in the ordinary course of business before the USPTO or the relevant international patent authority, as applicable, and no such application has been abandoned, withdrawn, or rejected with finality.

4.3 No Prior Assignments. The Grantor has not previously assigned, transferred, pledged, hypothecated, or otherwise encumbered any of the IP Collateral to any person or entity, other than (a) as set forth in, and in accordance with the terms of, the Security Agreement and (b) as contemplated by the existing negative pledge covenant under the equipment financing facility with Ridgeline Capital Partners LLC. No financing statement, recordation, or other filing or registration covering any of the IP Collateral is on file in any public office or with the USPTO, other than filings made on behalf of the Collateral Agent in connection with the transactions contemplated by the Loan Documents.

4.4 Schedule Completeness. Schedules A and B attached hereto constitute a complete and accurate listing of all of the Grantor's United States patents, patent applications, trademarks, trademark registrations, and trademark applications as of the date hereof. As of the date hereof, the Grantor's patent portfolio consists of fourteen (14) issued United States patents and seven (7) pending Patent Cooperation Treaty ("PCT") applications, all of which have been validly assigned to the Grantor and are reflected on Schedule A. The Grantor has no issued United States patents or pending United States patent applications that are not listed on Schedule A. The Grantor's trademark portfolio is as reflected on Schedule B, and the Grantor has no United States trademark registrations or pending United States trademark applications that are not listed on Schedule B.

SECTION 5. COVENANTS OF THE GRANTOR

The Grantor hereby covenants and agrees with the Collateral Agent and the Secured Parties as follows, which covenants shall remain in effect until the termination of this Agreement in accordance with Section 9 hereof:

5.1 Maintenance of IP. The Grantor shall, at its own cost and expense:

(a) maintain, prosecute, and diligently pursue each patent and patent application listed on Schedule A hereto, including by timely responding to all office actions, requests for information, and other communications from the USPTO or any other patent authority;

(b) pay all maintenance fees, annuities, renewal fees, and other charges required to maintain in force each issued patent and each pending patent application listed on Schedule A hereto when the same become due and payable;

(c) not abandon, disclaim, forfeit, dedicate to the public, or permit to lapse any item of IP Collateral without the prior written consent of the Collateral Agent (acting at the direction of the Required Lenders under the Bridge Loan Agreement), except where the failure to maintain such item of IP Collateral would not reasonably be expected to have a Material Adverse Effect (as defined in the Bridge Loan Agreement); and

(d) promptly, and in any event within ten (10) Business Days, notify the Collateral Agent in writing of any material adverse development with respect to any item of IP Collateral, including, without limitation, any challenge, opposition, interference proceeding, inter partes review, post-grant review, cancellation proceeding, or other administrative or judicial action instituted by any third party or governmental authority.

5.2 No Transfers. The Grantor shall not sell, assign, transfer, license exclusively, or otherwise dispose of any item of IP Collateral, or enter into any agreement to do any of the foregoing, except as expressly permitted by, and in compliance with, the terms and conditions of the Security Agreement and the Bridge Loan Agreement. Non-exclusive licenses granted by the Grantor in the ordinary course of business that are permitted under the Bridge Loan Agreement shall not be deemed a violation of this Section 5.2.

5.3 Infringement. The Grantor shall promptly notify the Collateral Agent of any infringement, misappropriation, dilution, or other violation of any IP Collateral of which the Grantor becomes aware, including any assertion by a third party that any IP Collateral is invalid or unenforceable. The Grantor shall take commercially reasonable steps to protect, defend, and enforce its rights in and to the IP Collateral, including, where appropriate, the institution of legal proceedings against infringers or misappropriators.

5.4 Future IP. If the Grantor, at any time after the date hereof, obtains rights to any new patents, patent applications, trademarks, trademark registrations, or trademark applications in the United States (whether by filing, issuance, registration, acquisition, assignment, or otherwise), the Grantor shall promptly, and in any event within thirty (30) days following such acquisition or filing, execute and deliver to the Collateral Agent a supplement to the applicable Schedule hereto (in substantially the form of Exhibit A attached hereto), together with any additional documents, instruments, or agreements reasonably necessary for recording with the USPTO, in order to subject such new intellectual property to the security interest created hereby. Any such newly acquired intellectual property shall automatically be deemed to be part of the IP Collateral from and after the date of acquisition thereof, regardless of whether a supplement has been executed and delivered.

SECTION 6. RECORDATION

This Agreement and any supplements hereto may be recorded with the USPTO in the Assignment Division of the USPTO, or with such other offices or agencies as the Collateral Agent may deem appropriate, in order to perfect the security interest of the Collateral Agent in the IP Collateral and to provide constructive notice thereof to third parties.

The Grantor hereby authorizes and requests the Commissioner for Patents and the Commissioner for Trademarks, as applicable, to record this Agreement and any supplements hereto. The Grantor shall cooperate with the Collateral Agent and shall execute and deliver any additional documents, instruments, or certificates as may be reasonably requested by the Collateral Agent in connection with the recording of this Agreement or any supplement hereto.

SECTION 7. REMEDIES

Upon the occurrence and during the continuance of an Event of Default (as defined in the Bridge Loan Agreement), the Collateral Agent shall have, in addition to all rights and remedies available under the Security Agreement and applicable law (including, without limitation, the California Uniform Commercial Code, the United States Patent Act, and the Lanham Act), the right to take any and all actions necessary or appropriate to enforce the security interest in the IP Collateral, including, without limitation:

(a) the right to license, sublicense, assign, sell, or otherwise dispose of any or all of the IP Collateral, in whole or in part, at public or private sale, in one or more transactions, and on such terms as the Collateral Agent may determine in its commercially reasonable judgment;

(b) the right to take possession and control of the IP Collateral and to exercise all rights of the Grantor with respect thereto, including the right to prosecute, defend, and maintain all patents and patent applications and to renew and maintain all trademarks and trademark registrations;

(c) the right to execute and deliver any assignments, transfers, or other instruments with respect to the IP Collateral, in the name of the Grantor or otherwise, as may be necessary or appropriate to effectuate any sale, license, or other disposition of the IP Collateral; and

(d) the right to collect and receive all income, royalties, damages, claims, and payments with respect to the IP Collateral.

The Collateral Agent may exercise such rights and remedies without demand upon or notice to the Grantor, except as may be required by applicable law that cannot be waived.

SECTION 8. POWER OF ATTORNEY

The Grantor hereby irrevocably appoints the Collateral Agent as its true and lawful attorney-in-fact, with full power of substitution and delegation, effective upon the occurrence and during the continuance of an Event of Default, to execute and file any document, instrument, or certificate, to take any action, and to make any payment that the Collateral Agent determines is necessary or desirable to maintain, protect, or enforce the IP Collateral and the security interest granted herein. The powers granted to the Collateral Agent under this Section 8 include, without limitation:

(a) the filing of assignments, amendments, continuations, responses to office actions, petitions, and any other documents with the USPTO or any other governmental authority;

(b) the payment of maintenance fees, annuities, renewal fees, and other charges required to maintain the IP Collateral;

(c) the institution, prosecution, defense, or settlement of any legal or administrative proceeding relating to the IP Collateral; and

(d) the execution and delivery of any documents or instruments necessary to transfer or assign the IP Collateral to a purchaser or transferee in connection with any enforcement action.

This power of attorney is coupled with an interest and is irrevocable until the termination of this Agreement in accordance with Section 9 hereof. The Grantor hereby ratifies and confirms all actions that the Collateral Agent may lawfully take pursuant to this power of attorney.

SECTION 9. TERMINATION

This Agreement and the security interest granted herein shall terminate upon the earlier of: (a) the indefeasible payment in full, in cash, of all Secured Obligations and the termination or expiration of all commitments of the Lenders under the Bridge Loan Agreement; and (b) the release of the IP Collateral in accordance with the terms and conditions of the Security Agreement.

Upon such termination, the Collateral Agent shall, at the Grantor's sole cost and expense, promptly execute and deliver to the Grantor such instruments, documents, and releases as may be reasonably necessary to release and terminate of record the security interest in the IP Collateral, including, without limitation, the filing of termination statements under the California Uniform Commercial Code and the recording of releases of security interests with the USPTO. Until such termination, this Agreement shall remain in full force and effect.

SECTION 10. MISCELLANEOUS

10.1 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California, without regard to any conflict-of-laws principles that would require the application of the law of any other jurisdiction, consistent with the governing law provision set forth in Section 11.9 of the Bridge Loan Agreement; provided, however, that to the extent the perfection, priority, or enforcement of the security interest granted herein is governed by federal patent or trademark law, such federal law shall apply.

10.2 Amendments. This Agreement may not be amended, modified, supplemented, or waived except by a written instrument duly executed by the Grantor and the Collateral Agent (acting at the direction of the Required Lenders, i.e., Lenders holding more than fifty percent (50%) of the aggregate commitments under the Bridge Loan Agreement). No failure or delay by the Collateral Agent in exercising any right, power, or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, power, or remedy preclude any other or further exercise thereof or the exercise of any other right, power, or remedy.

10.3 Successors and Assigns. This Agreement shall be binding upon the Grantor and its successors, transferees, and assigns and shall inure to the benefit of the Collateral Agent, the Secured Parties, and their respective successors, transferees, and assigns. The Grantor may not assign its obligations under this Agreement without the prior written consent of the Collateral Agent (acting at the direction of the Required Lenders).

10.4 Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or by electronic transmission in portable document format (.pdf) shall be effective as delivery of a manually executed counterpart.

10.5 Severability. If any provision of this Agreement is held to be invalid, illegal, or unenforceable in any respect by a court of competent jurisdiction, such invalidity, illegality, or unenforceability shall not affect any other provision hereof, and the remaining provisions of this Agreement shall continue in full force and effect. The Parties shall endeavor in good faith negotiations to replace any invalid, illegal, or unenforceable provision with a valid provision that achieves, to the greatest extent possible, the economic, business, and other purposes of the invalid provision.

10.6 Notices. All notices, requests, demands, consents, and other communications required or permitted under this Agreement shall be in writing and shall be delivered in accordance with the notice provisions set forth in the Security Agreement, to the following addresses (or such other address as a Party may designate in writing from time to time):

If to the Grantor:

Genome Dx Therapeutics Inc. 450 Genome Way, Suite 300 South San Francisco, California 94080

Attention: Miriam Sato, General Counsel

Email: msato@genomedx.com

If to the Collateral Agent:

Pacific Fiduciary Services Inc. 350 Mission Street, Suite 1200 San Francisco, California 94105

Attention: David Nakamura, Vice President, Corporate Trust

Email: dnakamura@pacificfiduciary.com

10.7 Entire Agreement. This Agreement, together with the Security Agreement, the Bridge Loan Agreement, and the other Loan Documents, constitutes the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior agreements, understandings, negotiations, and discussions, whether oral or written, relating to such subject matter.

[Signature Pages Follow]

SIGNATURE PAGE TO INTELLECTUAL PROPERTY SECURITY AGREEMENT

IN WITNESS WHEREOF, the Parties hereto have caused this intellectual Property Security Agreement to be duly executed and delivered by their respective authorized officers as of the date first written above.

GRANTOR:

GENOME DX THERAPEUTICS INC.

By: ________

Name: Dr. Ananya Mehta

Title: Chief Executive Officer

Date: March 6, 2026

COLLATERAL AGENT:

PACIFIC FIDUCIARY SERVICES INC., as Collateral Agent for the benefit of the Secured Parties

By: ________

Name: David Nakamura

Title: Vice President, Corporate Trust

Date: March 6, 2026

SCHEDULE A

TO INTELLECTUAL PROPERTY SECURITY AGREEMENT

PATENTS AND PATENT APPLICATIONS

The following is a complete listing of all United States patents and patent applications owned by Genome Dx Therapeutics Inc. (the "Grantor") as of March 6, 2026. All patents and patent applications listed below have been duly assigned to the Grantor and are recorded in the records of the United States Patent and Trademark Office.

Part I — Issued United States Patents

Part II — Pending Patent Applications (PCT Applications)

Note: The foregoing PCT applications are international filings under the Patent Cooperation Treaty. National phase entries in the United States, if any, shall be identified separately and supplemented to this Schedule A pursuant to Section 5.4 of this Agreement promptly upon the filing of any such national phase application with the USPTO.

SCHEDULE B

TO INTELLECTUAL PROPERTY SECURITY AGREEMENT

TRADEMARKS AND TRADEMARK APPLICATIONS

The following is a listing of all United States trademark registrations and trademark applications owned by Genome Dx Therapeutics Inc. (the "Grantor") as of March 6, 2026.

This Schedule B shall be supplemented in accordance with Section 5.4 of this Agreement upon the filing of any additional trademark applications or the issuance of any additional trademark registrations by the Grantor.

EXHIBIT A

FORM OF SUPPLEMENT TO SCHEDULES

OF INTELLECTUAL PROPERTY SECURITY AGREEMENT

SUPPLEMENT NO. [___] TO INTELLECTUAL PROPERTY SECURITY AGREEMENT

Date: ____

This Supplement No. [_] (this "Supplement") is delivered pursuant to Section 5.4 of that certain intellectual Property Security Agreement, dated as of March 6, 2026 (as supplemented from time to time, the "IP Security Agreement"), by and between Genome Dx Therapeutics Inc., a Delaware corporation (the "Grantor"), and Pacific Fiduciary Services Inc., a California corporation (the "Collateral Agent"), acting for the benefit of the Secured Parties. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the IP Security Agreement or, if not defined therein, in the Security Agreement (as defined in the IP Security Agreement).

The Grantor hereby notifies the Collateral Agent that, since the date of the IP Security Agreement (or the date of the most recent Supplement thereto, as applicable), the Grantor has acquired rights to, filed, or obtained the following intellectual property:

A. New Patents and/or Patent Applications (Supplement to Schedule A)

B. New Trademarks and/or Trademark Applications (Supplement to Schedule B)

Certification. The Grantor hereby certifies that:

1. Each item of intellectual property listed above is owned solely and exclusively by the Grantor.

2. Each item of intellectual property listed above is subject to the security interest granted under the IP Security Agreement and the Security Agreement in favor of the Collateral Agent for the benefit of the Secured Parties.

3. The representations and warranties of the Grantor set forth in Section 4 of the IP Security Agreement are true and correct in all material respects with respect to each item of intellectual property listed above, as of the date hereof.

4. The Grantor has not assigned, transferred, pledged, or otherwise encumbered any of the intellectual property listed above, other than as contemplated by the IP Security Agreement and the Security Agreement.

The Grantor hereby authorizes the Collateral Agent to record this Supplement with the United States Patent and Trademark Office and to take any other action reasonably necessary to perfect the security interest of the Collateral Agent in the intellectual property listed above.

IN WITNESS WHEREOF, the undersigned has executed this Supplement as of the date first written above.

GRANTOR:

GENOME DX THERAPEUTICS INC.

By: ________

Name: ________

Title: ________

Date: ________

Acknowledged and Received by:

COLLATERAL AGENT:

PACIFIC FIDUCIARY SERVICES INC., as Collateral Agent for the benefit of the Secured Parties

By: ________

Name: ________

Title: ________

Date: ________

Item No.	Title of Patent	U.S. Patent No.	Issue Date	Inventor(s)
1	RNA-Based Diagnostic Platform for Detection of Neurodegenerative Biomarkers	10,234,567	June 18, 2019	Dr. Ananya Mehta; Dr. James L. Whitfield
2	Modified Antisense Oligonucleotide Compositions for CNS Delivery	10,456,789	October 22, 2019	Dr. Ananya Mehta; Dr. Priya Ramanathan
3	Methods for Quantitative RNA Expression Profiling in Cerebrospinal Fluid	10,678,901	February 11, 2020	Dr. James L. Whitfield; Dr. Sarah K. Ling
4	Nanoparticle-Encapsulated RNA Therapeutic Constructs for Blood-Brain Barrier Penetration	10,891,234	July 7, 2020	Dr. Ananya Mehta; Dr. Robert Chen; Dr. Priya Ramanathan
5	Synthetic RNA Sequences Targeting Tau Protein Misfolding in Progressive Supranuclear Palsy	11,012,345	November 3, 2020	Dr. Ananya Mehta; Dr. James L. Whitfield
6	Companion Diagnostic Assay for Patient Stratification in RNA Therapeutic Trials	11,123,456	March 16, 2021	Dr. Sarah K. Ling; Dr. Michael Okafor
7	Lipid Nanoparticle Formulations with Enhanced CNS Tropism	11,234,567	August 10, 2021	Dr. Robert Chen; Dr. Priya Ramanathan
8	Methods of Treating Frontotemporal Dementia Using Targeted RNA Degraders	11,345,678	January 25, 2022	Dr. Ananya Mehta; Dr. James L. Whitfield; Dr. Michael Okafor
9	High-Throughput Screening Platform for RNA-Protein Interaction Modulators	11,456,789	May 17, 2022	Dr. Sarah K. Ling; Dr. Robert Chen
10	Stabilized mRNA Constructs for Sustained Expression of Neuroprotective Proteins	11,567,890	September 6, 2022	Dr. Ananya Mehta; Dr. Priya Ramanathan
11	GDT-2701: RNA Therapeutic Composition and Methods of Use for Amyotrophic Lateral Sclerosis	11,678,901	February 14, 2023	Dr. Ananya Mehta; Dr. James L. Whitfield; Dr. Robert Chen
12	Intrathecal Delivery Device and Methods for Controlled Release of RNA Therapeutics	11,789,012	July 18, 2023	Dr. Robert Chen; Dr. Michael Okafor
13	Biomarker Panel for Monitoring Treatment Response in Neurodegenerative Disease Patients	11,890,123	December 5, 2023	Dr. Sarah K. Ling; Dr. James L. Whitfield
14	Next-Generation RNA Backbone Modifications for Enhanced Nuclease Resistance and Tissue Specificity	12,012,345	June 11, 2024	Dr. Ananya Mehta; Dr. Priya Ramanathan; Dr. Robert Chen
Item No.	Title of Application	Application No. / PCT No.	Filing Date	Inventor(s)	Status
1	Dual-Target RNA Therapeutic Constructs for Synergistic Neuroprotection	PCT/US2024/031456	April 15, 2024	Dr. Ananya Mehta; Dr. James L. Whitfield	International Phase — Pending
2	AI-Guided Patient Selection Methods for RNA Therapeutic Clinical Trials	PCT/US2024/038912	June 28, 2024	Dr. Sarah K. Ling; Dr. Michael Okafor	International Phase — Pending
3	Engineered Exosome Delivery Vehicles for CNS-Targeted RNA Therapeutics	PCT/US2024/045678	September 10, 2024	Dr. Robert Chen; Dr. Priya Ramanathan	International Phase — Pending
4	Combination Therapy Comprising GDT-2701 and Small Molecule Chaperones for Treatment of ALS	PCT/US2024/052341	November 22, 2024	Dr. Ananya Mehta; Dr. James L. Whitfield; Dr. Robert Chen	International Phase — Pending
5	Non-Invasive Cerebrospinal Fluid Sampling Methods for RNA Biomarker Detection	PCT/US2025/005678	January 30, 2025	Dr. Sarah K. Ling; Dr. Michael Okafor	International Phase — Pending
6	Self-Amplifying RNA Platform for Treatment of Rare Lysosomal Storage Disorders with CNS Manifestations	PCT/US2025/012345	March 18, 2025	Dr. Ananya Mehta; Dr. Priya Ramanathan	International Phase — Pending
7	Multiplexed Diagnostic Assay for Simultaneous Detection of Multiple Neurodegenerative Disease Markers	PCT/US2025/019876	August 5, 2025	Dr. Sarah K. Ling; Dr. James L. Whitfield; Dr. Michael Okafor	International Phase — Pending
Item No.	Mark	U.S. Registration No. / Application No.	Registration / Filing Date	Status
1	GENOMEDX	Reg. No. 6,345,891	Registered: September 14, 2021	Registered — Active

2	GENOME DX THERAPEUTICS (and design)	Reg. No. 6,512,304	Registered: March 8, 2022	Registered — Active
3	GDT-2701	App. No. 97/654,321	Filed: October 3, 2025	Pending — Awaiting Examination
Item No.	Title	Registration No. / Application No.	Issue Date / Filing Date	Inventor(s)
Item No.	Mark	Registration No. / Application No.	Registration Date / Filing Date	Status

INTELLECTUAL PROPERTY SECURITY AGREEMENT
(Short-Form Patent and Trademark Security Agreement for Recording with the United States Patent and Trademark Office)
March 6, 2026
This INTELLECTUAL PROPERTY SECURITY AGREEMENT (this "Agreement") is entered into as of March 6, 2026, by and between:
GENOME DX THERAPEUTICS INC., a Delaware corporation (the "Grantor" or "GenomeDx"), with its principal place of business at 450 Genome Way, Suite 300, South San Francisco, California 94080;
and
PACIFIC FIDUCIARY SERVICES INC., a California corporation (the "Collateral Agent"), with its principal office at 350 Mission Street, Suite 1200, San Francisco, California 94105, acting in its capacity as Collateral Agent for the benefit of the Secured Parties (as defined in the Security Agreement referenced below).
The Grantor and the Collateral Agent are sometimes referred to herein individually as a "Party" and collectively as the "Parties."
RECITALS
WHEREAS:
A. GenomeDx, Pinnacle Venture Lending Corp., a Delaware corporation, in its capacity as Administrative Agent and a Lender, Cobalt Life Sciences Fund III, L.P., a Delaware limited partnership, in its capacity as a Lender, and Pacific Fiduciary Services Inc., in its capacity as Collateral Agent, have entered into that certain Bridge Loan Agreement, dated as of March 6, 2026 (as may be amended, restated, supplemented, or otherwise modified from time to time, the "Bridge Loan Agreement"), providing for a senior secured bridge loan facility in the aggregate principal amount of Fifteen Million Dollars ($15,000,000);
B. GenomeDx, as Grantor, and Pacific Fiduciary Services Inc., as Collateral Agent, have entered into that certain Security Agreement, dated as of March 6, 2026 (as may be amended, restated, supplemented, or otherwise modified from time to time, the "Security Agreement"), pursuant to which the Grantor granted to the Collateral Agent, for the benefit of the Secured Parties, a first-priority security interest in substantially all of the Grantor's assets, including, without limitation, its intellectual property;
C. This intellectual Property Security Agreement is being executed and delivered to supplement the Security Agreement and for the specific purpose of recording the Collateral Agent's security interest in the Grantor's patents, patent applications, trademarks, and trademark applications with the United States Patent and Trademark Office (the "USPTO"), in order to provide notice-filing perfection with respect to registered intellectual property collateral and to satisfy the requirements of 35 U.S.C. § 261 and 15 U.S.C. § 1060 with respect to security interests in patents and trademarks, respectively;
D. GenomeDx is the sole and exclusive owner of the patents, patent applications, trademarks, and trademark applications listed on the Schedules attached hereto and incorporated herein by reference; and
E. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Security Agreement or, if not defined therein, in the Bridge Loan Agreement.
NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
SECTION 1. GRANT OF SECURITY INTEREST
The Grantor hereby grants, assigns, and pledges to the Collateral Agent, for the ratable benefit of the Secured Parties, a continuing first-priority security interest in and to all of the Grantor's right, title, and interest in, to, and under the following property, whether now owned or hereafter acquired (collectively, the "IP Collateral"):
(a) All patents and patent applications of the United States listed on Schedule A attached hereto and incorporated herein by reference, together with all reissues, continuations, continuations-in-part, divisionals, extensions, renewals, and re-examinations thereof, and all rights therein provided by international treaties or conventions (collectively, the "Patent Collateral");
(b) All trademarks, service marks, trade names, trade dress, trademark applications, and trademark registrations of the United States, if any, listed on Schedule B attached hereto and incorporated herein by reference, together with all renewals, extensions, and applications therefor and the goodwill of the business connected with the use of and symbolized by such trademarks (collectively, the "Trademark Collateral");
(c) All rights to sue or otherwise recover for past, present, and future infringement, misappropriation, dilution, or other violation of any of the foregoing, including the right to collect damages, profits, and any other monetary relief;
(d) All licenses, sublicenses, royalties, income, payments, and other rights and benefits arising from or relating to any of the foregoing, whether now existing or hereafter arising; and
(e) All proceeds and products of any and all of the foregoing, in whatever form, including cash, negotiable instruments, and other forms of payment or exchange.
The grant of the security interest set forth in this Section 1 supplements, and does not in any way limit, restrict, or modify, the security interest granted under the Security Agreement. The IP Collateral constitutes a subset of the "Collateral" (as defined in the Security Agreement), and the security interest granted herein is subject to the same exceptions, limitations, and carve-outs set forth in the Security Agreement, including, without limitation, the exclusion of assets subject to the first-priority lien of Ridgeline Capital Partners LLC under GenomeDx's existing equipment financing facility, as more particularly described in the Bridge Loan Agreement, and the intercreditor arrangements set forth in that certain Intercreditor Agreement, dated as of March 6, 2026, by and among the Collateral Agent, Ridgeline Capital Partners LLC, and the Grantor (the "Intercreditor Agreement").
SECTION 2. SECURED OBLIGATIONS
The security interest granted herein secures the prompt and complete payment and performance of all Secured Obligations (as defined in the Security Agreement), including, without limitation, all obligations of the Grantor arising under or in connection with (a) the Bridge Loan Agreement, including all principal, interest, fees, premiums, indemnities, and expenses payable thereunder, (b) the Security Agreement, (c) the Warrant Agreements (as defined in the Bridge Loan Agreement), and (d) all other Loan Documents (as defined in the Bridge Loan Agreement), in each case whether now existing or hereafter arising, direct or indirect, absolute or contingent, and howsoever evidenced.
SECTION 3. RELATIONSHIP TO SECURITY AGREEMENT
This Agreement supplements the Security Agreement and shall be construed in conjunction with and as an integral part of the Security Agreement. Nothing contained herein shall be deemed to amend, modify, limit, or otherwise affect the scope or terms of the security interest granted under the Security Agreement, which security interest remains in full force and effect in accordance with its terms.
In the event of any conflict or inconsistency between the terms of this Agreement and the terms of the Security Agreement, the terms of the Security Agreement shall govern and control in all respects.
The rights and remedies of the Collateral Agent hereunder are in addition to, and not in limitation of, the rights and remedies available to the Collateral Agent and the Secured Parties under the Security Agreement, the Bridge Loan Agreement, and applicable law, including the California Uniform Commercial Code and the federal patent and trademark statutes of the United States.
SECTION 4. REPRESENTATIONS AND WARRANTIES OF THE GRANTOR
The Grantor hereby represents and warrants to the Collateral Agent and the Secured Parties as follows, each of which representations and warranties shall survive the execution and delivery of this Agreement:
4.1 Ownership. The Grantor is the sole and exclusive owner of the entire right, title, and interest in and to each item of IP Collateral listed on Schedules A and B hereto, free and clear of all liens, claims, encumbrances, charges, and security interests other than Permitted Liens (as defined in the Bridge Loan Agreement) and the security interest created hereby. No other person or entity has any ownership interest, legal or equitable, in any of the IP Collateral, except as may be expressly reflected on the face of the applicable Schedule.
4.2 Validity. To the Grantor's knowledge, after reasonable inquiry, each issued patent listed on Schedule A hereto is valid and enforceable, and no claim of invalidity or unenforceability has been asserted against any such patent by any third party. Each pending patent application listed on Schedule A hereto is being duly and diligently prosecuted in the ordinary course of business before the USPTO or the relevant international patent authority, as applicable, and no such application has been abandoned, withdrawn, or rejected with finality.
4.3 No Prior Assignments. The Grantor has not previously assigned, transferred, pledged, hypothecated, or otherwise encumbered any of the IP Collateral to any person or entity, other than (a) as set forth in, and in accordance with the terms of, the Security Agreement and (b) as contemplated by the existing negative pledge covenant under the equipment financing facility with Ridgeline Capital Partners LLC. No financing statement, recordation, or other filing or registration covering any of the IP Collateral is on file in any public office or with the USPTO, other than filings made on behalf of the Collateral Agent in connection with the transactions contemplated by the Loan Documents.
4.4 Schedule Completeness. Schedules A and B attached hereto constitute a complete and accurate listing of all of the Grantor's United States patents, patent applications, trademarks, trademark registrations, and trademark applications as of the date hereof. As of the date hereof, the Grantor's patent portfolio consists of fourteen (14) issued United States patents and seven (7) pending Patent Cooperation Treaty ("PCT") applications, all of which have been validly assigned to the Grantor and are reflected on Schedule A. The Grantor has no issued United States patents or pending United States patent applications that are not listed on Schedule A. The Grantor's trademark portfolio is as reflected on Schedule B, and the Grantor has no United States trademark registrations or pending United States trademark applications that are not listed on Schedule B.
SECTION 5. COVENANTS OF THE GRANTOR
The Grantor hereby covenants and agrees with the Collateral Agent and the Secured Parties as follows, which covenants shall remain in effect until the termination of this Agreement in accordance with Section 9 hereof:
5.1 Maintenance of IP. The Grantor shall, at its own cost and expense:
(a) maintain, prosecute, and diligently pursue each patent and patent application listed on Schedule A hereto, including by timely responding to all office actions, requests for information, and other communications from the USPTO or any other patent authority;
(b) pay all maintenance fees, annuities, renewal fees, and other charges required to maintain in force each issued patent and each pending patent application listed on Schedule A hereto when the same become due and payable;
(c) not abandon, disclaim, forfeit, dedicate to the public, or permit to lapse any item of IP Collateral without the prior written consent of the Collateral Agent (acting at the direction of the Required Lenders under the Bridge Loan Agreement), except where the failure to maintain such item of IP Collateral would not reasonably be expected to have a Material Adverse Effect (as defined in the Bridge Loan Agreement); and
(d) promptly, and in any event within ten (10) Business Days, notify the Collateral Agent in writing of any material adverse development with respect to any item of IP Collateral, including, without limitation, any challenge, opposition, interference proceeding, inter partes review, post-grant review, cancellation proceeding, or other administrative or judicial action instituted by any third party or governmental authority.
5.2 No Transfers. The Grantor shall not sell, assign, transfer, license exclusively, or otherwise dispose of any item of IP Collateral, or enter into any agreement to do any of the foregoing, except as expressly permitted by, and in compliance with, the terms and conditions of the Security Agreement and the Bridge Loan Agreement. Non-exclusive licenses granted by the Grantor in the ordinary course of business that are permitted under the Bridge Loan Agreement shall not be deemed a violation of this Section 5.2.
5.3 Infringement. The Grantor shall promptly notify the Collateral Agent of any infringement, misappropriation, dilution, or other violation of any IP Collateral of which the Grantor becomes aware, including any assertion by a third party that any IP Collateral is invalid or unenforceable. The Grantor shall take commercially reasonable steps to protect, defend, and enforce its rights in and to the IP Collateral, including, where appropriate, the institution of legal proceedings against infringers or misappropriators.
5.4 Future IP. If the Grantor, at any time after the date hereof, obtains rights to any new patents, patent applications, trademarks, trademark registrations, or trademark applications in the United States (whether by filing, issuance, registration, acquisition, assignment, or otherwise), the Grantor shall promptly, and in any event within thirty (30) days following such acquisition or filing, execute and deliver to the Collateral Agent a supplement to the applicable Schedule hereto (in substantially the form of Exhibit A attached hereto), together with any additional documents, instruments, or agreements reasonably necessary for recording with the USPTO, in order to subject such new intellectual property to the security interest created hereby. Any such newly acquired intellectual property shall automatically be deemed to be part of the IP Collateral from and after the date of acquisition thereof, regardless of whether a supplement has been executed and delivered.
SECTION 6. RECORDATION
This Agreement and any supplements hereto may be recorded with the USPTO in the Assignment Division of the USPTO, or with such other offices or agencies as the Collateral Agent may deem appropriate, in order to perfect the security interest of the Collateral Agent in the IP Collateral and to provide constructive notice thereof to third parties.
The Grantor hereby authorizes and requests the Commissioner for Patents and the Commissioner for Trademarks, as applicable, to record this Agreement and any supplements hereto. The Grantor shall cooperate with the Collateral Agent and shall execute and deliver any additional documents, instruments, or certificates as may be reasonably requested by the Collateral Agent in connection with the recording of this Agreement or any supplement hereto.
SECTION 7. REMEDIES
Upon the occurrence and during the continuance of an Event of Default (as defined in the Bridge Loan Agreement), the Collateral Agent shall have, in addition to all rights and remedies available under the Security Agreement and applicable law (including, without limitation, the California Uniform Commercial Code, the United States Patent Act, and the Lanham Act), the right to take any and all actions necessary or appropriate to enforce the security interest in the IP Collateral, including, without limitation:
(a) the right to license, sublicense, assign, sell, or otherwise dispose of any or all of the IP Collateral, in whole or in part, at public or private sale, in one or more transactions, and on such terms as the Collateral Agent may determine in its commercially reasonable judgment;
(b) the right to take possession and control of the IP Collateral and to exercise all rights of the Grantor with respect thereto, including the right to prosecute, defend, and maintain all patents and patent applications and to renew and maintain all trademarks and trademark registrations;
(c) the right to execute and deliver any assignments, transfers, or other instruments with respect to the IP Collateral, in the name of the Grantor or otherwise, as may be necessary or appropriate to effectuate any sale, license, or other disposition of the IP Collateral; and
(d) the right to collect and receive all income, royalties, damages, claims, and payments with respect to the IP Collateral.
The Collateral Agent may exercise such rights and remedies without demand upon or notice to the Grantor, except as may be required by applicable law that cannot be waived.
SECTION 8. POWER OF ATTORNEY
The Grantor hereby irrevocably appoints the Collateral Agent as its true and lawful attorney-in-fact, with full power of substitution and delegation, effective upon the occurrence and during the continuance of an Event of Default, to execute and file any document, instrument, or certificate, to take any action, and to make any payment that the Collateral Agent determines is necessary or desirable to maintain, protect, or enforce the IP Collateral and the security interest granted herein. The powers granted to the Collateral Agent under this Section 8 include, without limitation:
(a) the filing of assignments, amendments, continuations, responses to office actions, petitions, and any other documents with the USPTO or any other governmental authority;
(b) the payment of maintenance fees, annuities, renewal fees, and other charges required to maintain the IP Collateral;
(c) the institution, prosecution, defense, or settlement of any legal or administrative proceeding relating to the IP Collateral; and
(d) the execution and delivery of any documents or instruments necessary to transfer or assign the IP Collateral to a purchaser or transferee in connection with any enforcement action.
This power of attorney is coupled with an interest and is irrevocable until the termination of this Agreement in accordance with Section 9 hereof. The Grantor hereby ratifies and confirms all actions that the Collateral Agent may lawfully take pursuant to this power of attorney.
SECTION 9. TERMINATION
This Agreement and the security interest granted herein shall terminate upon the earlier of: (a) the indefeasible payment in full, in cash, of all Secured Obligations and the termination or expiration of all commitments of the Lenders under the Bridge Loan Agreement; and (b) the release of the IP Collateral in accordance with the terms and conditions of the Security Agreement.
Upon such termination, the Collateral Agent shall, at the Grantor's sole cost and expense, promptly execute and deliver to the Grantor such instruments, documents, and releases as may be reasonably necessary to release and terminate of record the security interest in the IP Collateral, including, without limitation, the filing of termination statements under the California Uniform Commercial Code and the recording of releases of security interests with the USPTO. Until such termination, this Agreement shall remain in full force and effect.
SECTION 10. MISCELLANEOUS
10.1 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California, without regard to any conflict-of-laws principles that would require the application of the law of any other jurisdiction, consistent with the governing law provision set forth in Section 11.9 of the Bridge Loan Agreement; provided, however, that to the extent the perfection, priority, or enforcement of the security interest granted herein is governed by federal patent or trademark law, such federal law shall apply.
10.2 Amendments. This Agreement may not be amended, modified, supplemented, or waived except by a written instrument duly executed by the Grantor and the Collateral Agent (acting at the direction of the Required Lenders, i.e., Lenders holding more than fifty percent (50%) of the aggregate commitments under the Bridge Loan Agreement). No failure or delay by the Collateral Agent in exercising any right, power, or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, power, or remedy preclude any other or further exercise thereof or the exercise of any other right, power, or remedy.
10.3 Successors and Assigns. This Agreement shall be binding upon the Grantor and its successors, transferees, and assigns and shall inure to the benefit of the Collateral Agent, the Secured Parties, and their respective successors, transferees, and assigns. The Grantor may not assign its obligations under this Agreement without the prior written consent of the Collateral Agent (acting at the direction of the Required Lenders).
10.4 Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or by electronic transmission in portable document format (.pdf) shall be effective as delivery of a manually executed counterpart.
10.5 Severability. If any provision of this Agreement is held to be invalid, illegal, or unenforceable in any respect by a court of competent jurisdiction, such invalidity, illegality, or unenforceability shall not affect any other provision hereof, and the remaining provisions of this Agreement shall continue in full force and effect. The Parties shall endeavor in good faith negotiations to replace any invalid, illegal, or unenforceable provision with a valid provision that achieves, to the greatest extent possible, the economic, business, and other purposes of the invalid provision.
10.6 Notices. All notices, requests, demands, consents, and other communications required or permitted under this Agreement shall be in writing and shall be delivered in accordance with the notice provisions set forth in the Security Agreement, to the following addresses (or such other address as a Party may designate in writing from time to time):
If to the Grantor:
Genome Dx Therapeutics Inc. 450 Genome Way, Suite 300 South San Francisco, California 94080
Attention: Miriam Sato, General Counsel
Email: msato@genomedx.com
If to the Collateral Agent:
Pacific Fiduciary Services Inc. 350 Mission Street, Suite 1200 San Francisco, California 94105
Attention: David Nakamura, Vice President, Corporate Trust
Email: dnakamura@pacificfiduciary.com
10.7 Entire Agreement. This Agreement, together with the Security Agreement, the Bridge Loan Agreement, and the other Loan Documents, constitutes the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior agreements, understandings, negotiations, and discussions, whether oral or written, relating to such subject matter.
[Signature Pages Follow]
SIGNATURE PAGE TO INTELLECTUAL PROPERTY SECURITY AGREEMENT
IN WITNESS WHEREOF, the Parties hereto have caused this intellectual Property Security Agreement to be duly executed and delivered by their respective authorized officers as of the date first written above.
GRANTOR:
GENOME DX THERAPEUTICS INC.
By: ________
Name: Dr. Ananya Mehta
Title: Chief Executive Officer
Date: March 6, 2026
COLLATERAL AGENT:
PACIFIC FIDUCIARY SERVICES INC., as Collateral Agent for the benefit of the Secured Parties
By: ________
Name: David Nakamura
Title: Vice President, Corporate Trust
Date: March 6, 2026
SCHEDULE A
TO INTELLECTUAL PROPERTY SECURITY AGREEMENT
PATENTS AND PATENT APPLICATIONS
The following is a complete listing of all United States patents and patent applications owned by Genome Dx Therapeutics Inc. (the "Grantor") as of March 6, 2026. All patents and patent applications listed below have been duly assigned to the Grantor and are recorded in the records of the United States Patent and Trademark Office.
Part I — Issued United States Patents
Part II — Pending Patent Applications (PCT Applications)
Note: The foregoing PCT applications are international filings under the Patent Cooperation Treaty. National phase entries in the United States, if any, shall be identified separately and supplemented to this Schedule A pursuant to Section 5.4 of this Agreement promptly upon the filing of any such national phase application with the USPTO.
SCHEDULE B
TO INTELLECTUAL PROPERTY SECURITY AGREEMENT
TRADEMARKS AND TRADEMARK APPLICATIONS
The following is a listing of all United States trademark registrations and trademark applications owned by Genome Dx Therapeutics Inc. (the "Grantor") as of March 6, 2026.
This Schedule B shall be supplemented in accordance with Section 5.4 of this Agreement upon the filing of any additional trademark applications or the issuance of any additional trademark registrations by the Grantor.
EXHIBIT A
FORM OF SUPPLEMENT TO SCHEDULES
OF INTELLECTUAL PROPERTY SECURITY AGREEMENT
SUPPLEMENT NO. [___] TO INTELLECTUAL PROPERTY SECURITY AGREEMENT
Date: ____
This Supplement No. [_] (this "Supplement") is delivered pursuant to Section 5.4 of that certain intellectual Property Security Agreement, dated as of March 6, 2026 (as supplemented from time to time, the "IP Security Agreement"), by and between Genome Dx Therapeutics Inc., a Delaware corporation (the "Grantor"), and Pacific Fiduciary Services Inc., a California corporation (the "Collateral Agent"), acting for the benefit of the Secured Parties. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the IP Security Agreement or, if not defined therein, in the Security Agreement (as defined in the IP Security Agreement).
The Grantor hereby notifies the Collateral Agent that, since the date of the IP Security Agreement (or the date of the most recent Supplement thereto, as applicable), the Grantor has acquired rights to, filed, or obtained the following intellectual property:
A. New Patents and/or Patent Applications (Supplement to Schedule A)
B. New Trademarks and/or Trademark Applications (Supplement to Schedule B)
Certification.  The Grantor hereby certifies that:
1.  Each item of intellectual property listed above is owned solely and exclusively by the Grantor.
2.  Each item of intellectual property listed above is subject to the security interest granted under the IP Security Agreement and the Security Agreement in favor of the Collateral Agent for the benefit of the Secured Parties.
3.  The representations and warranties of the Grantor set forth in Section 4 of the IP Security Agreement are true and correct in all material respects with respect to each item of intellectual property listed above, as of the date hereof.
4.  The Grantor has not assigned, transferred, pledged, or otherwise encumbered any of the intellectual property listed above, other than as contemplated by the IP Security Agreement and the Security Agreement.
The Grantor hereby authorizes the Collateral Agent to record this Supplement with the United States Patent and Trademark Office and to take any other action reasonably necessary to perfect the security interest of the Collateral Agent in the intellectual property listed above.
IN WITNESS WHEREOF, the undersigned has executed this Supplement as of the date first written above.
GRANTOR:
GENOME DX THERAPEUTICS INC.
By: ________
Name: ________
Title: ________
Date: ________
Acknowledged and Received by:
COLLATERAL AGENT:
PACIFIC FIDUCIARY SERVICES INC., as Collateral Agent for the benefit of the Secured Parties
By: ________
Name: ________
Title: ________
Date: ________
Item No. | Title of Patent | U.S. Patent No. | Issue Date | Inventor(s)
1 | RNA-Based Diagnostic Platform for Detection of Neurodegenerative Biomarkers | 10,234,567 | June 18, 2019 | Dr. Ananya Mehta; Dr. James L. Whitfield
2 | Modified Antisense Oligonucleotide Compositions for CNS Delivery | 10,456,789 | October 22, 2019 | Dr. Ananya Mehta; Dr. Priya Ramanathan
3 | Methods for Quantitative RNA Expression Profiling in Cerebrospinal Fluid | 10,678,901 | February 11, 2020 | Dr. James L. Whitfield; Dr. Sarah K. Ling
4 | Nanoparticle-Encapsulated RNA Therapeutic Constructs for Blood-Brain Barrier Penetration | 10,891,234 | July 7, 2020 | Dr. Ananya Mehta; Dr. Robert Chen; Dr. Priya Ramanathan
5 | Synthetic RNA Sequences Targeting Tau Protein Misfolding in Progressive Supranuclear Palsy | 11,012,345 | November 3, 2020 | Dr. Ananya Mehta; Dr. James L. Whitfield
6 | Companion Diagnostic Assay for Patient Stratification in RNA Therapeutic Trials | 11,123,456 | March 16, 2021 | Dr. Sarah K. Ling; Dr. Michael Okafor
7 | Lipid Nanoparticle Formulations with Enhanced CNS Tropism | 11,234,567 | August 10, 2021 | Dr. Robert Chen; Dr. Priya Ramanathan
8 | Methods of Treating Frontotemporal Dementia Using Targeted RNA Degraders | 11,345,678 | January 25, 2022 | Dr. Ananya Mehta; Dr. James L. Whitfield; Dr. Michael Okafor
9 | High-Throughput Screening Platform for RNA-Protein Interaction Modulators | 11,456,789 | May 17, 2022 | Dr. Sarah K. Ling; Dr. Robert Chen
10 | Stabilized mRNA Constructs for Sustained Expression of Neuroprotective Proteins | 11,567,890 | September 6, 2022 | Dr. Ananya Mehta; Dr. Priya Ramanathan
11 | GDT-2701: RNA Therapeutic Composition and Methods of Use for Amyotrophic Lateral Sclerosis | 11,678,901 | February 14, 2023 | Dr. Ananya Mehta; Dr. James L. Whitfield; Dr. Robert Chen
12 | Intrathecal Delivery Device and Methods for Controlled Release of RNA Therapeutics | 11,789,012 | July 18, 2023 | Dr. Robert Chen; Dr. Michael Okafor
13 | Biomarker Panel for Monitoring Treatment Response in Neurodegenerative Disease Patients | 11,890,123 | December 5, 2023 | Dr. Sarah K. Ling; Dr. James L. Whitfield
14 | Next-Generation RNA Backbone Modifications for Enhanced Nuclease Resistance and Tissue Specificity | 12,012,345 | June 11, 2024 | Dr. Ananya Mehta; Dr. Priya Ramanathan; Dr. Robert Chen
Item No. | Title of Application | Application No. / PCT No. | Filing Date | Inventor(s) | Status
1 | Dual-Target RNA Therapeutic Constructs for Synergistic Neuroprotection | PCT/US2024/031456 | April 15, 2024 | Dr. Ananya Mehta; Dr. James L. Whitfield | International Phase — Pending
2 | AI-Guided Patient Selection Methods for RNA Therapeutic Clinical Trials | PCT/US2024/038912 | June 28, 2024 | Dr. Sarah K. Ling; Dr. Michael Okafor | International Phase — Pending
3 | Engineered Exosome Delivery Vehicles for CNS-Targeted RNA Therapeutics | PCT/US2024/045678 | September 10, 2024 | Dr. Robert Chen; Dr. Priya Ramanathan | International Phase — Pending
4 | Combination Therapy Comprising GDT-2701 and Small Molecule Chaperones for Treatment of ALS | PCT/US2024/052341 | November 22, 2024 | Dr. Ananya Mehta; Dr. James L. Whitfield; Dr. Robert Chen | International Phase — Pending
5 | Non-Invasive Cerebrospinal Fluid Sampling Methods for RNA Biomarker Detection | PCT/US2025/005678 | January 30, 2025 | Dr. Sarah K. Ling; Dr. Michael Okafor | International Phase — Pending
6 | Self-Amplifying RNA Platform for Treatment of Rare Lysosomal Storage Disorders with CNS Manifestations | PCT/US2025/012345 | March 18, 2025 | Dr. Ananya Mehta; Dr. Priya Ramanathan | International Phase — Pending
7 | Multiplexed Diagnostic Assay for Simultaneous Detection of Multiple Neurodegenerative Disease Markers | PCT/US2025/019876 | August 5, 2025 | Dr. Sarah K. Ling; Dr. James L. Whitfield; Dr. Michael Okafor | International Phase — Pending
Item No. | Mark | U.S. Registration No. / Application No. | Registration / Filing Date | Status
1 | GENOMEDX | Reg. No. 6,345,891 | Registered: September 14, 2021 | Registered — Active
2 | GENOME DX THERAPEUTICS (and design) | Reg. No. 6,512,304 | Registered: March 8, 2022 | Registered — Active
3 | GDT-2701 | App. No. 97/654,321 | Filed: October 3, 2025 | Pending — Awaiting Examination
Item No. | Title | Registration No. / Application No. | Issue Date / Filing Date | Inventor(s)
Item No. | Mark | Registration No. / Application No. | Registration Date / Filing Date | Status

INTELLECTUAL PROPERTY SECURITY AGREEMENT

RECITALS

WHEREAS:

SECTION 1. GRANT OF SECURITY INTEREST

SECTION 2. SECURED OBLIGATIONS

SECTION 3. RELATIONSHIP TO SECURITY AGREEMENT

SECTION 4. REPRESENTATIONS AND WARRANTIES OF THE GRANTOR

SECTION 5. COVENANTS OF THE GRANTOR

SECTION 6. RECORDATION

SECTION 7. REMEDIES

SECTION 8. POWER OF ATTORNEY

SECTION 9. TERMINATION

SECTION 10. MISCELLANEOUS

SIGNATURE PAGE TO INTELLECTUAL PROPERTY SECURITY AGREEMENT

GRANTOR:

GENOME DX THERAPEUTICS INC.

COLLATERAL AGENT:

SCHEDULE A

TO INTELLECTUAL PROPERTY SECURITY AGREEMENT

PATENTS AND PATENT APPLICATIONS

SCHEDULE B

TO INTELLECTUAL PROPERTY SECURITY AGREEMENT

TRADEMARKS AND TRADEMARK APPLICATIONS

EXHIBIT A

FORM OF SUPPLEMENT TO SCHEDULES

OF INTELLECTUAL PROPERTY SECURITY AGREEMENT

GRANTOR:

GENOME DX THERAPEUTICS INC.

COLLATERAL AGENT:

Record

Parties

Dates

Amounts